BCLSI
Bain Capital Life Sciences Investors Portfolio holdings
AUM
$799M
This Quarter Return
+32.52%
1 Year Return
+36.47%
3 Year Return
+278.05%
5 Year Return
+363.53%
10 Year Return
–
AUM
$971M
AUM Growth
+$971M
(+21%)
Cap. Flow
+$12.8M
Cap. Flow
% of AUM
1.32%
Top 10 Holdings %
Top 10 Hldgs %
68.82%
Holding
35
New
1
Increased
4
Reduced
3
Closed
3
Top Buys
| 1 |
NewAmsterdam Pharma
NAMS
|
$25.8M |
| 2 |
Cabaletta Bio
CABA
|
$25.8M |
| 3 |
Pharvaris
PHVS
|
$25.6M |
| 4 |
X4 Pharmaceuticals
XFOR
|
$7.29M |
| 5 |
Annexon
ANNX
|
$2.87M |
Top Sells
| 1 |
Disc Medicine
IRON
|
$29.2M |
| 2 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$19.8M |
| 3 |
Dynavax Technologies
DVAX
|
$19.4M |
| 4 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$3.59M |
| 5 |
Spyre Therapeutics
SYRE
|
$1.55M |
Sector Composition
| 1 | Healthcare | 98.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $151M | 15.54% | 3,577,267 | – | – |
|
|
2
NewAmsterdam Pharma
NAMS
$2.71B
| $125M | 12.83% | 10,473,913 +2,173,913 | +26% | +$25.8M |
|
|
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
| $80.8M | 8.32% | 3,081,307 | – | – |
|
|
4
Pharvaris
PHVS
$1.39B
| $73.7M | 7.59% | 4,868,784 +1,688,183 | +53% | +$25.6M |
|
|
5
Disc Medicine
IRON
$2.07B
| $59.2M | 6.09% | 1,332,548 -658,366 | -33% | -$29.2M |
|
6
Crinetics Pharmaceuticals
CRNX
$2.92B
| $41.5M | 4.28% | 2,305,558 | – | – |
|
7
Savara
SVRA
$567M
| $37.1M | 3.82% | 11,622,598 | – | – |
|
8
Aclaris Therapeutics
ACRS
$209M
| $35.3M | 3.63% | 3,400,000 | – | – |
|
9
Natera
NTRA
$23.1B
| $34.1M | 3.51% | 700,197 | – | – |
|
|
10
Dynavax Technologies
DVAX
$1.19B
| $31.2M | 3.21% | 2,415,000 -1,500,000 | -38% | -$19.4M |
|
|
11
X4 Pharmaceuticals
XFOR
$84.2M
| $31M | 3.19% | 15,960,588 +3,758,078 | +31% | +$7.29M |
|
12
Arcutis Biotherapeutics
ARQT
$1.86B
| $28.6M | 2.94% | 3,000,000 | – | – |
|
13
Mersana Therapeutics
MRSN
$36.5M
| $28.5M | 2.94% | 8,663,673 | – | – |
|
|
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
| $27.4M | 2.82% | 2,500,000 | – | – |
|
|
15
Cabaletta Bio
CABA
$133M
| $25.8M | 2.66% | +2,000,000 | New | +$25.8M |
|
|
16
Annexon
ANNX
$226M
| $20.1M | 2.07% | 5,701,926 +815,310 | +17% | +$2.87M |
|
|
EQRX
17
DELISTED
EQRx, Inc. Common Stock
EQRX
| $18.6M | 1.92% | 10,003,573 | – | – |
|
18
Nurix Therapeutics
NRIX
$714M
| $18.2M | 1.88% | 1,822,883 | – | – |
|
19
Solid Biosciences
SLDB
$427M
| $16.4M | 1.69% | 3,130,422 | – | – |
|
|
MRNS
20
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $15.5M | 1.6% | 1,431,058 | – | – |
|
|
TSVT
21
DELISTED
2seventy bio
TSVT
| $14.3M | 1.47% | 1,408,901 | – | – |
|
22
Atea Pharmaceuticals
AVIR
$267M
| $9.3M | 0.96% | 2,485,638 | – | – |
|
23
Rapid Micro Biosystems
RPID
$107M
| $8.43M | 0.87% | 8,434,560 | – | – |
|
24
Nautilus Biotechnolgy
NAUT
$85.9M
| $7.74M | 0.8% | 2,000,000 | – | – |
|
25
Xilio Therapeutics
XLO
$36.3M
| $7.35M | 0.76% | 2,805,413 | – | – |
|